Hansa Biopharma AB (publ) (HNSA.ST)
SEK 29.58
(10.7%)
SEK 29.58
(10.7%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -831.72 Million SEK | -36.09% |
| 2022 | -611.13 Million SEK | -11.46% |
| 2021 | -548.28 Million SEK | -30.28% |
| 2020 | -420.85 Million SEK | -16.9% |
| 2019 | -360 Million SEK | -45.18% |
| 2018 | -247.97 Million SEK | -40.37% |
| 2017 | -176.66 Million SEK | -58.97% |
| 2016 | -111.12 Million SEK | -67.7% |
| 2015 | -66.26 Million SEK | -128.17% |
| 2014 | -29.04 Million SEK | -65.37% |
| 2013 | -17.56 Million SEK | -6.66% |
| 2012 | -16.46 Million SEK | 32.99% |
| 2011 | -24.57 Million SEK | -30.4% |
| 2010 | -18.84 Million SEK | -19.17% |
| 2009 | -15.81 Million SEK | -518.1% |
| 2008 | -2.55 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -207.94 Million SEK | 4.87% |
| 2024 Q3 | -103.79 Million SEK | 50.08% |
| 2024 Q1 | -218.57 Million SEK | -75.62% |
| 2023 Q1 | -205.42 Million SEK | -38.17% |
| 2023 Q3 | -250.65 Million SEK | 0.21% |
| 2023 FY | -831.72 Million SEK | -36.09% |
| 2023 Q4 | -124.45 Million SEK | 50.35% |
| 2023 Q2 | -251.18 Million SEK | -22.28% |
| 2022 Q2 | -170.07 Million SEK | -22.85% |
| 2022 Q1 | -138.43 Million SEK | 15.27% |
| 2022 FY | -611.13 Million SEK | -11.46% |
| 2022 Q4 | -148.67 Million SEK | 3.43% |
| 2022 Q3 | -153.95 Million SEK | 9.48% |
| 2021 Q2 | -132.59 Million SEK | -27.58% |
| 2021 Q1 | -103.92 Million SEK | 1.8% |
| 2021 FY | -548.28 Million SEK | -30.28% |
| 2021 Q3 | -148.37 Million SEK | -11.9% |
| 2021 Q4 | -163.39 Million SEK | -10.12% |
| 2020 FY | -420.85 Million SEK | -16.9% |
| 2020 Q1 | -93.36 Million SEK | 15.77% |
| 2020 Q2 | -99.24 Million SEK | -6.29% |
| 2020 Q3 | -122.4 Million SEK | -23.34% |
| 2020 Q4 | -105.83 Million SEK | 13.54% |
| 2019 Q4 | -110.85 Million SEK | -17.6% |
| 2019 Q3 | -94.26 Million SEK | -14.38% |
| 2019 Q2 | -82.41 Million SEK | -13.7% |
| 2019 Q1 | -72.47 Million SEK | 10.77% |
| 2019 FY | -360 Million SEK | -45.18% |
| 2018 FY | -247.97 Million SEK | -40.37% |
| 2018 Q1 | -46.49 Million SEK | 5.08% |
| 2018 Q4 | -81.22 Million SEK | -32.18% |
| 2018 Q3 | -61.45 Million SEK | -4.52% |
| 2018 Q2 | -58.79 Million SEK | -26.45% |
| 2017 Q3 | -37.52 Million SEK | 16.89% |
| 2017 Q4 | -48.98 Million SEK | -30.54% |
| 2017 FY | -176.66 Million SEK | -58.97% |
| 2017 Q1 | -44.99 Million SEK | -34.09% |
| 2017 Q2 | -45.15 Million SEK | -0.35% |
| 2016 Q1 | -19.97 Million SEK | -4.56% |
| 2016 FY | -111.12 Million SEK | -67.7% |
| 2016 Q3 | -26.92 Million SEK | 12.21% |
| 2016 Q4 | -33.55 Million SEK | -24.62% |
| 2016 Q2 | -30.67 Million SEK | -53.54% |
| 2015 FY | -66.26 Million SEK | -128.17% |
| 2015 Q1 | -10.72 Million SEK | 16.02% |
| 2015 Q3 | -13.93 Million SEK | 38.09% |
| 2015 Q2 | -22.5 Million SEK | -109.84% |
| 2015 Q4 | -19.1 Million SEK | -37.12% |
| 2014 Q3 | -5.42 Million SEK | -11.9% |
| 2014 Q4 | -12.77 Million SEK | -135.41% |
| 2014 Q1 | -5.99 Million SEK | -34.45% |
| 2014 Q2 | -4.84 Million SEK | 19.17% |
| 2014 FY | -29.04 Million SEK | -65.37% |
| 2013 Q3 | -4.46 Million SEK | -3.27% |
| 2013 Q2 | -4.31 Million SEK | 0.0% |
| 2013 Q4 | -4.46 Million SEK | 0.0% |
| 2013 Q1 | -4.31 Million SEK | -28.21% |
| 2013 FY | -17.56 Million SEK | -6.66% |
| 2012 Q4 | -3.36 Million SEK | 0.0% |
| 2012 FY | -16.46 Million SEK | 32.99% |
| 2011 FY | -24.57 Million SEK | -30.4% |
| 2010 FY | -18.84 Million SEK | -19.17% |
| 2009 FY | -15.81 Million SEK | -518.1% |
| 2008 FY | -2.55 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | -1715.983% |
| Biovica International AB (publ) | -124.82 Million SEK | -566.32% |
| Cantargia AB (publ) | -280.02 Million SEK | -197.014% |
| CombiGene AB (publ) | -35.66 Million SEK | -2232.008% |
| Cyxone AB (publ) | -22.98 Million SEK | -3517.904% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -7022.11% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -4972.089% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -809.968% |
| Fluicell AB (publ) | -26.55 Million SEK | -3032.183% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -575.821% |
| Mendus AB (publ) | -101.61 Million SEK | -718.469% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -2143.587% |
| I-Tech AB | 20.2 Million SEK | 4216.814% |
| Intervacc AB (publ) | -102.85 Million SEK | -708.657% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -6757.85% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 6934.744% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -4547.259% |
| OncoZenge AB (publ) | -15.9 Million SEK | -5130.285% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -189790.411% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | -114.266% |
| Lipum AB (publ) | -37.17 Million SEK | -2137.129% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | -234.58% |
| Ziccum AB (publ) | -21.41 Million SEK | -3784.364% |
| BioArctic AB (publ) | 229.24 Million SEK | 462.802% |
| Genovis AB (publ.) | 61.5 Million SEK | 1452.39% |
| Camurus AB (publ) | 431.44 Million SEK | 292.777% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -367.681% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -1363.755% |
| Aptahem AB (publ) | -11.11 Million SEK | -7384.296% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | -167.484% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | -362.923% |
| Kancera AB (publ) | -64.88 Million SEK | -1181.758% |
| Saniona AB (publ) | -95.81 Million SEK | -768.093% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -1869.827% |
| AcouSort AB (publ) | -17.08 Million SEK | -4766.99% |
| Xintela AB (publ) | -54.08 Million SEK | -1437.858% |
| Abliva AB (publ) | -95.5 Million SEK | -770.829% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 15542.258% |
| Amniotics AB (publ) | -30.87 Million SEK | -2594.266% |
| 2cureX AB (publ) | -32.51 Million SEK | -2457.722% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -6383.63% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | -78.41% |
| Biosergen AB | -27.03 Million SEK | -2976.229% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -4933.711% |
| Corline Biomedical AB | -1.8 Million SEK | -45876.783% |
| NextCell Pharma AB | -41.95 Million SEK | -1882.182% |
| Nanologica AB (publ) | -75.15 Million SEK | -1006.643% |
| LIDDS AB (publ) | -40.2 Million SEK | -1968.646% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | -154.426% |
| BioInvent International AB (publ) | -330.3 Million SEK | -151.804% |
| SynAct Pharma AB | -215.81 Million SEK | -285.395% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -1787.956% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -3403.898% |
| Alzinova AB (publ) | -16.48 Million SEK | -4946.845% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -661.035% |
| Oncopeptides AB (publ) | -249.11 Million SEK | -233.875% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -8275.823% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -633.938% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -3843.483% |
| Simris Alg AB (publ) | -37.3 Million SEK | -2129.513% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -447.725% |